PRNewsWire
02 Jul 2026, 00:11 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the marketing authorization application for narsoplimab in the treatment of TA-TMA. — Regulatory rejection of a primary drug candidate typically leads to significant valuation loss and removes a key revenue catalyst.
-0.90Pomerantz LLP has launched an investigation into whether Omeros Corporation and its officers engaged in securities fraud or unlawful business practices. — The threat of class-action litigation introduces legal risk and potential financial liabilities for the company.
-0.40Which stocks this story touches
The company received a negative opinion from the EMA for a drug application and is now facing a securities fraud investigation.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
The company is the subject of an investigation by Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
